NCT01558960

Intravitreal Injections of Melphalan for Retinoblastoma

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials. Intra-arterial chemotherapy with Melphalan has shown success in some patients but with limited response when there is marked vitreal seeding. For these cases Intravitreal injections of Melphalan have been successful in Japan. In this study the same chemotherapy (melphalan) will be administered intravitreally (directly through the eye wall) and the response (short and long term) will be monitored.

Detailed description

Intravitreal injections of Melphalan will be given to cases unresponsive to chemotherapy or with vitreal seeding of the disease.

Conditions

• Retinoblastoma

Interventions

Type	Name	Description
DRUG	IVit Melphalan	IVit injections of Melphalan

Timeline

• Start date: 2012-03-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2012-03-20
• Last updated: 2015-08-20

Locations

1 site across 1 country: Israel